:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FCarawayTx_rgb_large1.png)
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FEyeBio-Logo.png){kind=logo}
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2FICGLOGO.jpg)
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FAutifony-logo-retina-updated.png)
13 June 2023Portfolio NewsAutifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FQuell.png)
9 June 2023Portfolio NewsUK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FQuell.png)
9 June 2023Portfolio NewsQuell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2Fpulmocide-logo.png)
8 June 2023Portfolio NewsPulmocide Announces Expansion of Management Team
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FImbria_Logo_Colour.png)
5 June 2023Portfolio NewsImbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FCumulus.png)
31 May 2023Portfolio NewsCumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FViolet-Therapeutics-Logo.jpg)
31 May 2023Portfolio NewsViolet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)- 19 May 2023SV NewsFirst Steps to Treating Dementia May Lie in Related Diseases
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2Ftherino-bio-logo.png)
15 May 2023Portfolio NewsTherini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FOphthotech-Corp.jpg)
1 May 2023Portfolio NewsAstellas Pharma buys Iveric Bio for $5.9 billion- 27 April 2023Portfolio NewsTherini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FNitrase.jpg)
18 April 2023Portfolio NewsNitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting
